Fred Hutchinson Cancer Research Center, Clinical Research Division, 1100 Fairview Avenue N, MS D5-380, PO Box 19024, Seattle, WA 98109, USA.
The first series of patients with metastatic renal cell carcinoma (RCC) treated by non-myeloablative allogeneic hematopoietic cell transplantation (HCT) was reported in 2000 and demonstrated an allogeneic graft-versus-tumor (GVT) effect that encouraged further investigation of this approach. However, the past 10 years have also witnessed profound changes in the medical management of metastatic RCC with the introduction of targeted therapies directed against VEGF or mammalian target of rapamycin (mTOR) signaling pathways creating uncertainty about a continued role for allogeneic HCT in the treatment of RCC.
A total of 21 published reports describing clinical outcomes for 398 patients with metastatic RCC treated by allogeneic HCT compiled herein provide a composite overview of the world wide experience for key efficacy and toxicity outcomes. Review of correlative studies that identify donor-derived T cells as mediators of RCC-specific GVT effects offers insight into both the potential as well as the technical barriers to the delivery of antigen-specific post-transplant cellular therapy or vaccination designed to augment the allogeneic GVT effect.
The future development of non-myeloablative allogeneic HCT for metastatic RCC will require novel treatment protocols designed to augment and sustain post-transplant GVT effects against RCC to generate renewed enthusiasm for this approach.
Written by:
Tykodi SS, Sandmaier BM, Warren EH, Thompson JA. Are you the author?
Reference: Expert Opin Biol Ther. 2011 Mar 21. Epub ahead of print.
doi: 10.1517/14712598.2011.566855
PubMed Abstract
PMID: 21417772
UroToday.com Renal Cancer Section
